Last $385.00 MXN
Change Today 0.00 / 0.00%
Volume 0.0
PFE* On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
London
Sao Paulo
Bogota
As of 4:09 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFE*) Snapshot

Open
$384.00
Previous Close
$385.00
Day High
$385.00
Day Low
$384.00
52 Week High
03/5/14 - $434.90
52 Week Low
08/12/14 - $369.18
Market Cap
2.4T
Average Volume 10 Days
4.4K
EPS TTM
--
Shares Outstanding
6.3B
EX-Date
07/30/14
P/E TM
--
Dividend
$1.01
Dividend Yield
3.49%
Current Stock Chart for PFIZER INC (PFE*)

pfizer inc (PFE*) Details

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. The company’s Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians for various therapeutic and disease areas comprising Alzheimer’s disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation. Its Specialty Care and Oncology segment provides prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. The company’s Established Products and Emerging Markets segment offers prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions, as well as sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. Its Consumer Healthcare segment provides non-prescription products in a range of therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company also offers Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Norvasc, Sutent, and the Premarin family of products; and consumer healthcare products under the Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H, and Robitussin brands. It serves wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and grocery and convenience stores. It has strategic alliance with CliniWorks (Israel) Ltd. to develop population health management platform with advanced analytics and patient care capabilities. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

77,700 Employees
Last Reported Date: 02/28/14
Founded in 1849

pfizer inc (PFE*) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.8M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.2M
President of Worldwide Research and Developme...
Total Annual Compensation: $1.1M
Group President of Global Innovative Pharma B...
Total Annual Compensation: $926.3K
Group President of Global Established Pharma ...
Total Annual Compensation: $810.1K
Compensation as of Fiscal Year 2013.

pfizer inc (PFE*) Key Developments

United States Food and Drug Administration Approves Updated Label for EMBEDA Extended-Release Capsules of Pfizer Inc

Pfizer Inc. announced that the United States Food and Drug Administration (FDA) has approved an updated label for EMBEDA(R) (morphine sulfate and naltrexone hydrochloride) extended-release (ER) capsules, for oral use, CII, to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal (i.e., snorting) routes when crushed. However, abuse of EMBEDA by these routes is still possible. The updated label also includes data from a human abuse potential study of intravenous (IV) morphine and naltrexone to simulate crushed EMBEDA. However, it is unknown whether the results with simulated crushed EMBEDA predict a reduction in abuse by the IV route until additional postmarketing data are available. EMBEDA is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Pfizer expects EMBEDA will be available in the U.S. in early 2015. EMBEDA capsules consist of extended-release morphine sulfate and sequestered naltrexone hydrochloride, an opioid antagonist. Naltrexone is intended to remain sequestered when the product is taken as directed. The in vitro and pharmacokinetic data demonstrate that crushing EMBEDA pellets results in the simultaneous release and rapid absorption of morphine sulfate and naltrexone hydrochloride.

Pfizer to Establish Oncology R&D Centre in Chile

Pfizer will launch an oncology research and development (R&D) centre in Macul, Chile, in 2015. Pfizer's centre in Chile will focus on the development of oncology treatments with special emphasis in the research of lung cancer treatments. The R&D center will require a total investment of USD 21 million, of which USD 7 million will be financed by Chile's Development Corporation.

Pfizer Announces FDA Acceptance of Palbociclib New Drug Application with Priority Review

Pfizer Inc. announced the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration (FDA). This NDA requests FDA approval of palbociclib, in combination with letrozole, as a first-line treatment for postmenopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have not received previous systemic treatment for their advanced disease. The submission is based on the final results of PALOMA-1, a randomized, Phase 2 trial comparing palbociclib plus letrozole versus letrozole alone in this population of patients. The FDA's Priority Review status accelerates the review time from 10 months to a goal of six months from the day of acceptance of filing and is given to drugs that may offer major advances in treatment or may provide a treatment where no adequate therapy exists. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is April 13, 2015. Palbociclib received Breakthrough Therapy designation from the FDA in April 2013, for the first-line systemic treatment of women with advanced or metastatic ER+, HER2- breast cancer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE*:MM $385.00 MXN 0.00

PFE* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $140.12 USD -0.81
Bayer AG €104.95 EUR +0.80
Gilead Sciences Inc $105.78 USD -0.89
Merck & Co Inc $55.51 USD +0.38
Novartis AG SFr.84.50 CHF +0.95
View Industry Companies
 

Industry Analysis

PFE*

Industry Average

Valuation PFE* Industry Range
Price/Earnings 17.8x
Price/Sales 3.6x
Price/Book 2.3x
Price/Cash Flow 12.2x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.